Modeling the combination of amphotericin B, micafungin, and nikkomycin Z against Aspergillus fumigatus in vitro using a novel response surface paradigm

被引:13
作者
Brun, Yseult F.
Dennis, Carly G.
Greco, William R.
Bernacki, Ralph J.
Pera, Paula J.
Bushey, Jennifer J.
Youn, Richard C.
White, Donald B.
Segal, Brahm H.
机构
[1] Roswell Pk Canc Inst, Dept Canc Prevent & Populat Sci, Buffalo, NY 14263 USA
[2] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA
[3] Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA
[4] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA
[5] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Dept Pharm Practice, Buffalo, NY USA
[6] Univ Toledo, Dept Math, Toledo, OH 43606 USA
[7] Univ Toledo, Dept Pharmacol, Toledo, OH 43606 USA
关键词
D O I
10.1128/AAC.01007-06
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Response surface methods for the study of multiple-agent interaction allow one to model all of the information present in full concentration -effect data sets and to visualize and quantify local regions of synergy, additivity, and antagonism. In randomized wells of 96-well plates, Aspergillus fumigatus was exposed to various combinations of amphotericin B, micafungin, and nikkomycin Z. The experimental design was comprised of 91 different fixed-ratio mixtures, all performed in quintuplicate. After 24 h of drug exposure, drug effect on fungal viability was assessed using the tetrazolium salt 2,3-bis {2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide} (XTT) assay. First, we modeled each fixed-ratio combination alone using the four-parameter Hill conce n tra tion- effect model. Then, we modeled each parameter, including the 50% inhibitory concentration (IC50) effect, versus the proportion of each agent using constrained polynomials. Finally, we modeled the three-agent response surface overall. The overall four-dimensional response surface was complex, but it can be explained in detail both analytically and graphically. The grand model that fit the best included complex polynomial equations for the slope parameter m and the combination index (equivalent to the IC50 for a fixed-ratio concentration, but with concentrations normalized by the respective IC(50)s of the drugs alone). There was a large region of synergy, mostly at the nikkomycin Z/micafungin edge of the ternary plots for equal normalized proportions of each drug and extending into the center of the plots. Applying this response surface method to a huge data set for a three-antifungal-agent combination is novel. This new paradigm has the potential to significantly advance the field of combination antifungal pharmacology.
引用
收藏
页码:1804 / 1812
页数:9
相关论文
共 33 条
[1]   METHOD FOR TESTING FOR SYNERGY WITH ANY NUMBER OF AGENTS [J].
BERENBAUM, MC .
JOURNAL OF INFECTIOUS DISEASES, 1978, 137 (02) :122-130
[2]   Modeling of the three antifungal agent combination (Amphotericin B plus Micafungin plus Nikkomycin Z) against Aspergillus fumigatus in vitro using a novel response surface paradigm. [J].
Brun, YF ;
Segal, BH ;
Dennis, CG ;
Youn, RC ;
White, DB ;
Greco, WR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) :P28-P28
[3]   Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus [J].
Chiou, CC ;
Mavrogiorgos, N ;
Tillem, E ;
Hector, R ;
Walsh, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (12) :3310-3321
[4]   Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus [J].
Cuenca-Estrella, M ;
Gomez-Lopez, A ;
Garcia-Effron, G ;
Alcazar-Fuoli, L ;
Mellado, E ;
Buitrago, MJ ;
Rodriguez-Tudela, JL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :1232-1235
[5]   Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis [J].
Denning, David W. ;
Marr, Kieren A. ;
Lau, Wendi M. ;
Facklam, David P. ;
Ratanatharathorn, Voravit ;
Becker, Cornelia ;
Ullmann, Andrew J. ;
Seibel, Nita L. ;
Flynn, Patricia M. ;
van Burik, Jo-Anne H. ;
Buell, Donald N. ;
Patterson, Thomas F. .
JOURNAL OF INFECTION, 2006, 53 (05) :337-349
[6]   Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease [J].
Dennis, CG ;
Greco, WR ;
Brun, Y ;
Youn, R ;
Slocum, HK ;
Bernacki, RJ ;
Lewis, R ;
Wiederhold, N ;
Holland, SM ;
Petraitiene, R ;
Walsh, TJ ;
Segal, BH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (02) :422-427
[7]   In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models [J].
Dorsthorst, DTAT ;
Verweij, PE ;
Meis, JFGM ;
Punt, NC ;
Mouton, JW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) :2007-2013
[8]  
Faessel HM, 1999, IN VITRO CELL DEV-AN, V35, P270
[9]   In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus [J].
Ganesan, LT ;
Manavathu, EK ;
Cutright, JL ;
Alangaden, GJ ;
Chandrasekar, PH .
CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (11) :961-966
[10]  
GRECO WR, 1990, CANCER RES, V50, P5318